Q4-FY26 · Nandini Piramal
We're currently anticipating revenue growth in the early to mid teens with EBITDA expected to grow faster than revenue supported by operating leverage.
PIRAMALPHARMA / language trends
Read confidence between the lines.
Piramal Pharma · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q4-FY26 · Peter D. Young
We actually saw our win rate increase last year versus the prior year. And we think that's because of a couple of factors.
Q4-FY26 · Nandini Piramal
We achieved a net promoter score of 60, surpassing the industry average and reflecting high levels of customer satisfaction.